Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V. Schwarzbold, Eduardo Sprinz, Parvinder K. Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C. Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G. Marchevsky, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J. Pollard, the AMPHEUS Project, Oxford COVID Vaccine Trial Team
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/2174b542d59f4531bfbfd908fa719572
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/2174b542d59f4531bfbfd908fa719572

Documents similaires